# To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization

Source: https://onco.cc/trials/nct06478719/  
OnCo record `nct06478719` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Placebo in hepatocellular carcinoma, run by Febico Biomedical Corp., now recruiting.

## Summary

To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization is a phase 1/2 interventional study registered as NCT06478719 by Febico Biomedical Corp., with 120 participants planned, started 2024-06-24 and due to reach its primary completion in 2028-06-07. Interventions recorded: Placebo and FB-1603.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06478719
- Phase: 1/2
- Setting: A Phase I/II Randomized, Double-blinded Study of FB-1603 to Evaluate the Safety and Efficacy in Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization (FECHT Trial)
- Sponsor: Febico Biomedical Corp.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06478719: https://clinicaltrials.gov/study/NCT06478719

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct06478719.json